DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy
NCT07024693 · Design Therapeutics, Inc.
Primary completion dateRecorded edit
− Previous value
2026-09
+ Updated value
2027-12
DSGN
Design Therapeutics, Inc.
Company identity checked against sources
See the trials and registry edits we have linked to this sponsor, the company or organization running a study. Choose “Follow company” to add it to your watchlist and find its recorded changes in your dashboard.
1Trials in this database
2Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal DystrophyNCT07024693 | DSGN | Phase 2 | Recruiting | 2027-12Estimated |
Latest recorded trial changes
DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy
NCT07024693 · Design Therapeutics, Inc.
Enrollment · participant countRecorded edit
− Previous value
count: 28; type: ESTIMATED
+ Updated value
count: 70; type: ESTIMATED